- Home
- CCD vs KROS Comparison
CCD vs KROS Comparison
Compare CCD & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCD
- KROS
- Stock Information
- Founded
- CCD 2014
- KROS 2015
- Country
- CCD United States
- KROS United States
- Employees
- CCD N/A
- KROS N/A
- Industry
- CCD Trusts Except Educational Religious and Charitable
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CCD Finance
- KROS Health Care
- Exchange
- CCD Nasdaq
- KROS Nasdaq
- Market Cap
- CCD 555.7M
- KROS 565.0M
- IPO Year
- CCD N/A
- KROS 2020
- Fundamental
- Price
- CCD $20.81
- KROS $15.59
- Analyst Decision
- CCD
- KROS Buy
- Analyst Count
- CCD 0
- KROS 14
- Target Price
- CCD N/A
- KROS $20.56
- AVG Volume (30 Days)
- CCD 96.1K
- KROS 487.1K
- Earning Date
- CCD 01-01-0001
- KROS 11-05-2025
- Dividend Yield
- CCD 10.61%
- KROS N/A
- EPS Growth
- CCD N/A
- KROS N/A
- EPS
- CCD N/A
- KROS 0.47
- Revenue
- CCD N/A
- KROS $232,844,000.00
- Revenue This Year
- CCD N/A
- KROS $5,579.44
- Revenue Next Year
- CCD N/A
- KROS N/A
- P/E Ratio
- CCD N/A
- KROS $33.50
- Revenue Growth
- CCD N/A
- KROS 85820.30
- 52 Week Low
- CCD $16.93
- KROS $9.12
- 52 Week High
- CCD $24.68
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- CCD 63.79
- KROS 60.26
- Support Level
- CCD $20.37
- KROS $15.38
- Resistance Level
- CCD $20.59
- KROS $16.07
- Average True Range (ATR)
- CCD 0.20
- KROS 0.66
- MACD
- CCD 0.05
- KROS 0.08
- Stochastic Oscillator
- CCD 88.88
- KROS 76.54
About CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.